Advertisement

How “Dara” You!

  • Mark T. Friedman
  • Kamille A. West
  • Peyman Bizargity
  • Kyle Annen
  • Jeffrey S. Jhang
Chapter

Abstract

A 73-year-old man with immunoglobulin (Ig)G kappa multiple myeloma is referred for outpatient transfusion due to severe anemia with hemoglobin (Hgb) of 6.6 g/dL. The patient has a history of red blood cell (RBC) transfusion at your hospital 2 years ago at which time the antibody screen was negative. An ethylenediaminetetraacetic acid (EDTA) anticoagulant sample is submitted to the blood bank for type and screen along with a request for two units of irradiated RBCs.

Keywords

Anti-CD38 Anti-CD47 Daratumumab Dithiothreitol/DTT Genotyping Multiple myeloma Trypsin 

References

  1. 1.
    Chapuy CI, Nicholson RT, Aquad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–54.CrossRefGoogle Scholar
  2. 2.
    DARZALEX® Prescribing Information. Janssen Biotech, Inc., Horsesham, PA; 2017.Google Scholar
  3. 3.
    Nedelcu E, Hall C, Stoner A, Eichbaum Q, Meena-Leist C. Interference of anti-CD47 therapy with blood bank testing. Transfusion. 2017;57(Suppl S3):148A.Google Scholar
  4. 4.
    Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in two cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128:1987–9.CrossRefGoogle Scholar
  5. 5.
    Bride KL, Vincent TL, Im S-Y, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL). Blood. 2018;131:995–9.CrossRefGoogle Scholar
  6. 6.
    Chari A, Arinsburg SA, Jagannath S, Satta T, Treadwell I, Catemero D, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51. http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30111-8/fulltext. Accessed 6 Jan 2018CrossRefGoogle Scholar

Recommended Reading

  1. Chari A, Arinsburg SA, Jagannath S, Satta T, Treadwell I, Catemero D, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51. http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(17)30111-8/fulltextCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Mark T. Friedman
    • 1
  • Kamille A. West
    • 2
  • Peyman Bizargity
    • 3
  • Kyle Annen
    • 4
  • Jeffrey S. Jhang
    • 1
  1. 1.Icahn School of MedicineMount Sinai Health SystemNew YorkUSA
  2. 2.Department of Transfusion MedicineNational Institutes of Health Clinical CenterBethesdaUSA
  3. 3.Department of Molecular & Human GeneticsBaylor College of MedicineHoustonUSA
  4. 4.Department of PathologyChildren’s Hospital ColoradoAuroraUSA

Personalised recommendations